Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-228 in East Asian patients with advanced nonhematological malignancies
NCT03370302Phase 1Terminated
- Sponsor
- Calithera Biosciences
- Start
- Jan 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 1, open-label trial of sapanisertib in malignant solid tumor (2 arms), sponsored by Calithera Biosciences. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events, Number of Participants With Grade 3 or Higher TEAEs and 9 more. Started Jan 2018; status: terminated.
02
Drugs
sapanisertib
03
Conditions
malignant solid tumor
Beyond the preview
Go deeper on NCT03370302.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03370302.